In fact, targeting sEH to increase protective epoxy fatty acids, such as EETs, but also to decrease the formation of pro-inflammatory diols derived from linoleic acid or omega-3 fatty acids in more advanced stage of the diabetic disease, represents a new pharmacological approach to treat the cardiovascular complications, the metabolic abnormalities and ocular complications of type 2 diabetes [3, 8, 30, 46, 47]. The gene discussed is EPHX2; the disease is type 2 diabetes mellitus.